New EGA group to promote access to ''value-added'' drugs
This article was originally published in Scrip
Executive Summary
The EGA, which represents generics and biosimilars companies in Europe, has set up a new internal group to help increase patient access to value-added off-patent medicines such as those that improve compliance or offer a different delivery route from the originator medicine.